Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.
|
31676865 |
2019 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction.
|
30439355 |
2019 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent incident venous thromboembolism risk to carriers of the established factor V Leiden p.R506Q and prothrombin G20210A mutations.
|
31676865 |
2019 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.
|
31420334 |
2019 |
Venous Thromboembolism
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Altered levels of factor (F)VIII, prothrombin, or antithrombin have been associated with an increased risk for venous thromboembolism (VTE).
|
30408635 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14-8.17) and anaemia (HR: 4.11; 95%CI: 1.45-11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68-10.1) were associated with at increased risk for major bleeding.
|
29499439 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
|
30121419 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
High prevalence of factor V Leiden and prothrombin G20101A mutations in Kashmiri patients with venous thromboembolism.
|
29454086 |
2018 |
Venous Thromboembolism
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Other biomarkers reviewed, which did not consistently demonstrate significant associations with VTE included prothrombin fragments F1 + 2, factor VIII, protein C, protein S, von Willebrand antigen and activity, antithrombin, thrombin antithrombin complex, antiphospholopid antibody, plasminogen activator inhibitor, tissue factor pathway inhibitor and several variants associated with known hypercoagulable states (factor V Leiden, prothrombin gene variant, methylenetetrahydrofolate reductase variant).
|
29407626 |
2018 |
Venous Thromboembolism
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
Prothrombin clotting activity was measured in 267 unrelated patients with unprovoked VTE.
|
29331940 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Factor V Leiden and factor II c.*97G>A (formerly referred to as prothrombin 20210G>A) are the two most common genetic variants associated with venous thromboembolism (VTE).
|
30297698 |
2018 |
Venous Thromboembolism
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
Measurement of serum D-dimer, fibrin degradation product, thrombin/antithrombin III complex, and prothrombin fragment 1 + 2 levels may be useful for the early detection of VTE in patients with advanced pancreatic carcinoma.
|
29682191 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
The predictive value of factor V Leiden and the G20210A prothrombin mutation regarding recurrent venous thromboembolism (VTE) is limited and does not influence subsequent patient management.
|
29922879 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
The child was also carrier of heterozygous prothrombin G20210A variant.Severe venous thromboembolism can occur in otherwise healthy children with complex inherited thrombophilia.
|
29536478 |
2018 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.
|
28373160 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
In this case-control study, we aimed to determine the frequency of prothrombin G20210A and factor V Leiden (FVL) G1691A polymorphisms and protein C, protein S, and antithrombin III deficiencies in the East Algerian population and to investigate whether these genetic factors are associated with VTE.
|
26304686 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Prothrombin mutation carriers and noncarriers had a comparable rate of venous thromboembolism recurrence (adjusted HR, 1.00; 95% CI, 0.68-1.48), major bleeding (adjusted HR, 0.75; 95% CI, 0.42-1.34), and nonmajor bleeding events (adjusted HR, 1.10; 95% CI, 0.77-1.57).
|
27986523 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
We studied 34 prothrombin mutation heterozygous carriers and sex- and age-matched 34 non-carriers, all at least three months since the first VTE episode, before and during treatment with rivaroxaban.
|
28771277 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?
|
28606797 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
In patients with venous thromboembolism (VTE) and factor V Leiden (FVL) or prothrombin 20210G-A mutation (PTM), the influence of gender on outcome has not been consistently studied.
|
28262227 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Weight loss, serous effusion, the absence of the EGFR mutation, poor performance status (PS), hypoalbuminemia, hyponatremia, long prothrombin time (PT), and elevated levels of C-reaction-protein (CRP) and D-dimer were found to be associated with an increased risk of VTE by univariate analyses.
|
29312712 |
2017 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
In women ≥35 years (<35 years), the individual probability of gestational VTE was as follows: 0.7% (0.5%) for heterozygous <i>FVL</i>; 3.4% (2.2%) for homozygous <i>FVL</i>; 0.6% (0.4%) for heterozygous prothrombin G20210A; 8.2% (5.5%) for compound heterozygotes for <i>FVL</i> and prothrombin G20210A; 9.0% (6.1%) for antithrombin deficiency; 1.1% (0.7%) for protein C deficiency; and 1.0% (0.7%) for protein S deficiency.
|
27613196 |
2016 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we describe a novel substitution affecting Arg596 of prothrombin molecule (Arginine596 to Tryptophan or p.Arg596Trp or Arg221aTrp in the chymotrypsinogen numbering system or prothrombin Padua 2) in 2 Italian families with venous thromboembolism.
|
27013614 |
2016 |
Venous Thromboembolism
|
0.500 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.
|
26908601 |
2016 |
Venous Thromboembolism
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Though several genes, such as antithrombin, protein C, protein S, factor V, and prothrombin are associated with the familial clustering of VTE, these loci only partially explain the familial aggregation of VTE.
|
27764883 |
2016 |